Steribrooks Penems Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 09-11-2024
- Paid Up Capital ₹ 0.18 M
as on 09-11-2024
- Company Age 4 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 8.00 M
as on 09-11-2024
- Revenue -94.94%
(FY 2023)
- Profit 344.47%
(FY 2023)
- Ebitda 318.24%
(FY 2023)
- Net Worth 102.20%
(FY 2023)
- Total Assets -50.22%
(FY 2023)
About Steribrooks Penems
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.18 M.
The company has closed loans amounting to ₹8.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Chhitiz Saraogi and Aditya Kumar serve as directors at the Company.
- CIN/LLPIN
U24232KA2020PTC135017
- Company No.
135017
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jun 2020
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Steribrooks Penems?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chhitiz Saraogi  | Director | 11-Jun-2024 | Current |
| Aditya Kumar | Director | 06-Jan-2021 | Current |
Financial Performance and Corporate Structure Insights of Steribrooks Penems.
Steribrooks Penems Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 94.94% decrease. The company also saw a substantial improvement in profitability, with a 344.47% increase in profit. The company's net worth Soared by an impressive increase of 102.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Steribrooks Penems?
In 2023, Steribrooks Penems had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Steriscience Specialties Private LimitedActive 4 years 3 monthsChhitiz Saraogi and Aditya Kumar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 01 Mar 2021 | ₹8.00 M | Satisfied |
How Many Employees Work at Steribrooks Penems?
Steribrooks Penems has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Steribrooks Penems, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Steribrooks Penems's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
